0.46
+0.0501(+12.27%)
Currency In USD
Address
47 Thorndike Street
Cambridge, MA 02141
United States of America
Phone
617 714 0360
Website
Sector
Healthcare
Industry
Biotechnology
Employees
52
First IPO Date
January 25, 2017
| Name | Title | Pay | Year Born |
| Mr. Douglas E. Onsi J.D. | Chief Financial Officer, General Counsel, Treasurer & Secretary, President, Chief Executive Officer & Director | 764,112 | 1969 |
| Mr. Augustine J. Lawlor | Chief Operating Officer | 578,731 | 1957 |
| Dr. Cynthia A. Sirard M.D. | Chief Medical Officer | 780,333 | 1970 |
| Ms. Christine M. Granfield | Vice President and Head of Regulatory Affairs & Quality | 0 | 1968 |
| Dr. Jason S. Baum Ph.D. | Chief Scientific Officer | 0 | 1979 |
| Mr. Mark O'Mahony | Chief Manufacturing Officer | 0 | 1971 |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.